![]() |
市場調查報告書
商品編碼
1368662
靜脈注射免疫球蛋白市場 - 副產品(IGG、IGA、IGM、IGD、IGE)、應用(低丙種球蛋白血症、CIDP、免疫缺陷疾病、重症肌無力、MMN、ITP)、配銷通路(醫院、專科)、全球預測,2023 - 2032Intravenous Immunoglobulin Market - By Product (IGG, IGA, IGM, IGD, IGE), Application (Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Myasthenia Gravis, MMN, ITP), Distribution Channel (Hospital, Specialty), Global Forecast, 2023 - 2032 |
在人口老化的推動下,2023 年至 2032 年全球靜脈免疫球蛋白市場規模的年複合成長率可能為 7.6%。根據國際貨幣基金組織的預測,全球預期壽命取得了顯著進步,從1913年的僅為34歲上升到2022年的72歲,並且這種上升趨勢預計將長期持續。同樣,2019年《世界人口展望》修訂版的資料顯示,到2050年,全球65歲以上人口的比例將從2019年的十一分之一(9%)增至六分之一(16%) 。此外到 2050 年,歐洲和北美將有四分之一的人年齡在 65 歲或以上。
隨著年齡的成長,人們的免疫系統可能會減弱,使他們更容易受到各種疾病和病症的影響。 IVIG 是治療各種自體免疫疾病和免疫缺陷疾病的重要方法。隨著全球老年人口的不斷成長,對 IVIG 作為治療選擇的需求不斷增加,為市場擴張和成長創造了有利的環境。
整個靜脈免疫球蛋白市場根據產品、應用、配銷通路和地區進行分類。
由於IgE靜脈注射免疫球蛋白在治療嚴重過敏性疾病和過敏反應中的特殊作用,到2032年,IgE靜脈注射免疫球蛋白產業將獲得值得注意的估值。隨著過敏變得越來越普遍,尤其是在已開發國家,對有效的過敏管理和治療的需求也越來越大。 IgE 免疫球蛋白為那些經歷危及生命的過敏反應的人提供有針對性的緩解,使其成為管理嚴重過敏和過敏反應的重要組成部分,從而推動了其需求。
重症肌無力領域的靜脈注射免疫球蛋白市場佔有率將在 2023 年至 2032 年期間顯著成長,因為由於其免疫調節作用,治療重症肌無力的 IVIG 的需求量很大。重症肌無力是一種自體免疫神經肌肉疾病,免疫系統會攻擊神經肌肉接頭,導致肌肉無力。 IVIG 療法有助於調節免疫反應並緩解症狀。隨著重症肌無力等自體免疫疾病的盛行率持續上升,對 IVIG 作為治療選擇的需求也增加。
由於多種因素,亞太地區靜脈注射免疫球蛋白(IVIG)產業正在不斷擴張。醫療基礎設施的不斷改進、IVIG 療法意識的提高以及人口老化的不斷加劇,導致該地區對免疫球蛋白產品的需求不斷增加。此外,該地區自體免疫和免疫缺陷疾病的激增需要 IVIG 治療。隨著醫療保健服務的改善和意識的傳播,亞太地區為 IVIG 行業提供了巨大的成長機會。
Global Intravenous Immunoglobulin Market size could exhibit 7.6% CAGR from 2023 to 2032, driven by the rise in the aging population. According to IMF projections, global life expectancy has shown remarkable progress, rising from just 34 years in 1913 to 72 years in 2022, and this upward trend is expected to persist over the long term. Similarly, data from the 2019 Revision of World Population Prospects reveals that by 2050, the proportion of people aged over 65 in the world will increase to one in six (16%), up from one in eleven (9%) in 2019. Furthermore, by 2050, as many as one in four individuals in Europe and Northern America may be 65 or older.
As people age, their immune systems may weaken, making them more susceptible to various diseases and conditions. IVIG is a crucial treatment for various autoimmune and immunodeficiency disorders. With a growing elderly demographic worldwide, the demand for IVIG as a therapeutic option is increasing, creating a favorable environment for market expansion and growth.
The overall Intravenous Immunoglobulin Market is categorized based on product, application, distribution channel, and region.
IgE Intravenous Immunoglobulin Industry will garner a noteworthy valuation by 2032 due to the specific role of IgE Intravenous Immunoglobulin in treating severe allergic conditions and anaphylactic reactions. As allergies become more prevalent, especially in developed nations, there's a growing need for effective allergy management and treatment. IgE immunoglobulin provides targeted relief for those experiencing life-threatening allergic responses, making it a vital component in managing severe allergies and anaphylaxis, thus driving its demand.
Intravenous immunoglobulin market share from the Myasthenia Gravis segment will grow commendably over 2023-2032 due to the high demand for IVIG in the treatment of Myasthenia Gravis owing to its immunomodulatory effects. Myasthenia Gravis is an autoimmune neuromuscular disorder where the immune system attacks neuromuscular junctions, leading to muscle weakness. IVIG therapy helps to modulate the immune response and alleviate symptoms. As the prevalence of autoimmune diseases like Myasthenia Gravis continues to rise, the demand for IVIG as a treatment option has increased.
Asia Pacific intravenous immunoglobulin (IVIG) industry is expanding due to multiple factors. Increasing healthcare infrastructure, rising awareness of IVIG therapies, and a growing aging population have contributed to the region's increased demand for immunoglobulin products. Moreover, a surge in autoimmune and immunodeficiency disorders in the region necessitates IVIG treatment. As healthcare access improves and awareness spreads, the Asia Pacific region offers significant growth opportunities for the IVIG industry.